Brain metastases during follow-up of children and adolescents with extracranial malignant germ cell tumors: Risk adapted management decision tree analysis based on data of the MAHO/MAKEI-registry

2012 ◽  
Vol 60 (2) ◽  
pp. 217-223 ◽  
Author(s):  
Ulrich Göbel ◽  
Rüdiger von Kries ◽  
Carmen Teske ◽  
Dominik T. Schneider ◽  
Andreas Beyerlein ◽  
...  
Keyword(s):  
Decision Tree ◽  
Brain Metastases ◽  
Germ Cell ◽  
Children And Adolescents ◽  
Germ Cell Tumors ◽  
Management Decision ◽  
Decision Tree Analysis ◽  
Tree Analysis ◽  
Malignant Germ Cell Tumors

scholarly journals Brain metastases of malignant germ cell tumors in children and adolescents

Cancer ◽  
2004 ◽  
Vol 101 (3) ◽  
pp. 620-626 ◽  
Author(s):  
Sheri L. Spunt ◽  
Michael F. Walsh ◽  
Matthew J. Krasin ◽  
Kathleen J. Helton ◽  
Catherine A. Billups ◽  
...  
Keyword(s):  
Brain Metastases ◽  
Germ Cell ◽  
Children And Adolescents ◽  
Germ Cell Tumors ◽  
Malignant Germ Cell Tumors

scholarly journals Reduced and Compressed Cisplatin-Based Chemotherapy in Children and Adolescents With Intermediate-Risk Extracranial Malignant Germ Cell Tumors: A Report From the Children’s Oncology Group

2017 ◽  
Vol 35 (11) ◽  
pp. 1203-1210 ◽  
Author(s):  
Furqan Shaikh ◽  
John W. Cullen ◽  
Thomas A. Olson ◽  
Farzana Pashankar ◽  
Marcio H. Malogolowkin ◽  
...  
Keyword(s):  
Germ Cell ◽  
Children And Adolescents ◽  
Statistical Significance ◽  
Germ Cell Tumors ◽  
Stage I ◽  
Stage Ii ◽  
Intermediate Risk ◽  
Historical Cohort ◽  
Number Of Cycles ◽  
Malignant Germ Cell Tumors

Purpose To investigate whether event-free survival (EFS) can be maintained among children and adolescents with intermediate-risk (IR) malignant germ cell tumors (MGCT) if the administration of cisplatin, etoposide, and bleomycin (PEb) is reduced from four to three cycles and compressed from 5 to 3 days per cycle. Patients and Methods In a phase 3, single-arm trial, patients with IR MGCT (stage II-IV testicular, II-III ovarian, I-II extragonadal, or stage I gonadal tumors with subsequent recurrence) received three cycles of PEb. A parametric comparator model specified that the observed EFS rate should not be significantly < 92%. As recommended for trials that test a reduction of therapy, a one-sided P value ≤ .10 was used to indicate statistical significance. In a post hoc analysis, we also compared results to the EFS rate of comparable patients treated with four cycles of PEb in two prior studies. Results Among 210 eligible patients enrolled from 2003 to 2011, 4-year EFS (EFS4) rate was 89% (95% confidence interval, 83% to 92%), which was significantly lower than the 92% threshold of the comparison model ( P = .08). Among 181 newly diagnosed patients, the EFS4 rate was 87%, compared with 92% for 92 comparable children in the historical cohort ( P = .15). The EFS4 rate was significantly associated with stage (stage I, 100%; stage II, 92%; stage III, 85%; and stage IV, 54%; P < .001). Conclusion The EFS rate for children with IR MGCT observed after three cycles of PEb was less than that of a prespecified parametric model, particularly for patients with higher-stage tumors. These data do not support a reduction in the number of cycles of PEb from four to three. However, further investigation of a reduction in the number of cycles for patients with lower-stage tumors is warranted.

Secondary neoplasms following treatment of malignant germ cell tumors.

1993 ◽  
Vol 11 (9) ◽  
pp. 1703-1709 ◽  
Author(s):  
C Bokemeyer ◽  
H J Schmoll
Keyword(s):  
Testicular Cancer ◽  
Germ Cell ◽  
Cumulative Incidence ◽  
Lymphoblastic Leukemia ◽  
Germ Cell Tumors ◽  
German Population ◽  
Secondary Neoplasms ◽  
Secondary Neoplasia ◽  
Malignant Germ Cell Tumors

PURPOSE The current study investigates the frequency and outcome of secondary malignancies in patients treated for testicular cancer at Hannover University Medical School between 1970 and 1990. PATIENTS AND METHODS One thousand twenty-five patients with a median follow-up duration of 61 months (range, 12 to 240) were included in the analysis. Follow-up was complete in 1,018 patients (99%). Histology was seminoma in 324 patients (38.7%) and nonseminomatous germ cell tumor in 624 patients (61.3%). At the time of median follow-up, 814 patients (79.9%) were alive. RESULTS Fourteen patients developed a secondary neoplasm (cumulative incidence, 1.38%; 95% confidence interval [CI], 0.75 to 2.30); 13 patients had solid tumors and one had secondary lymphoblastic leukemia with a t(4; 11) translocation including band 11q23. None of 224 patients on surveillance strategy (with or without retroperitoneal lymph node dissection [RPLND]) developed a second neoplasm, compared with four of 413 patients (0.97%; 95% CI, 0 to 1.9) after cisplatin-based chemotherapy (not significant) and nine of 332 patients (2.7%; 95% CI, 0.9 to 4.5) after radiotherapy (P = .02). The cumulative incidence of a secondary neoplasia of 1.76% (95% CI, 0.97 to 2.94) in patients treated by radiotherapy and/or chemotherapy was significantly higher compared with patients on surveillance protocols (P = .03). Chemotherapy containing standard-dose etoposide did not increase the risk of occurrence of secondary neoplasms. A significantly elevated relative risk of 7.53 (range, 3.4 to 14.3) compared with the male German population was only found for patients treated by radiotherapy. CONCLUSION Compared with patients who have other curable malignant tumors, an incidence of 1.38 of secondary neoplasms after a median follow-up duration of 61 months is low. The highest risk for secondary neoplasia after treatment of testicular cancer is associated with the use of radiotherapy. Following chemotherapy, no significantly elevated risk was observed. In conclusion, the benefits of curative treatment far outweigh the risk of secondary cancer in patients with malignant germ cell tumors.

Combination cisplatin, vinblastine, and bleomycin chemotherapy (PVB) for malignant germ-cell tumors of the ovary.

1983 ◽  
Vol 1 (10) ◽  
pp. 645-651 ◽  
Author(s):  
R W Carlson ◽  
B I Sikic ◽  
M M Turbow ◽  
S C Ballon
Keyword(s):  
Germ Cell ◽  
Recurrent Disease ◽  
Germ Cell Tumors ◽  
Stage I ◽  
Stage Iii ◽  
Treatment Toxicity ◽  
Malignant Germ Cell Tumors ◽  
Mixed Germ Cell Tumors

Nine women with germ-cell tumors of the ovary (three endodermal sinus tumors, four immature teratomas, and two mixed germ-cell tumors) were treated with cisplatin, vinblastine, and bleomycin (PVB) chemotherapy after cytoreductive operations. Five patients were stage I, three were stage III, and one patient had recurrent disease. All nine women are alive and without evidence of disease with a median follow-up of 31 months from diagnosis and 27 months since completion of PVB. Treatment toxicity although occasionally severe was rapidly reversible.

Outcome and staging evaluation in malignant germ cell tumors of the ovary in children and adolescents: an intergroup study

2004 ◽  
Vol 39 (3) ◽  
pp. 424-429 ◽  
Author(s):  
D Billmire ◽  
C Vinocur ◽  
F Rescorla ◽  
B Cushing ◽  
W London ◽  
...  
Keyword(s):  
Germ Cell ◽  
Children And Adolescents ◽  
Germ Cell Tumors ◽  
Malignant Germ Cell Tumors

scholarly journals Treatment outcome of patients with brain metastases from malignant germ cell tumors

Cancer ◽  
1999 ◽  
Vol 85 (4) ◽  
pp. 988-997 ◽  
Author(s):  
Sophie D. Foss� ◽  
Carsten Bokemeyer ◽  
Arthur Gerl ◽  
Stephane Culine ◽  
William G. Jones ◽  
...  
Keyword(s):  
Treatment Outcome ◽  
Brain Metastases ◽  
Germ Cell ◽  
Germ Cell Tumors ◽  
Malignant Germ Cell Tumors
Sign in / Sign up

Export Citation Format

Share Document